Captain T Cell — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Captain T Cell is a private, pre-clinical stage biotech developing TCR-based cell therapies for solid tumors. Operating from Munich, Germany, the company is in the early stages of building its technology platform and pipeline. As a pre-revenue entity, its success will depend on advancing its research, securing partnerships and funding, and navigating the complex development pathway for cell therapies.

Oncology

Technology Platform

T cell receptor (TCR) discovery and engineering platform for developing autologous or allogeneic T cell therapies targeting solid tumors.

Opportunities

The significant unmet need in treating solid tumors presents a vast market opportunity for effective cell therapies.

Advances in gene editing and cell manufacturing are creating enabling technologies for the next generation of TCR therapies.

Strategic partnerships with larger pharma companies could provide crucial funding, development expertise, and commercial reach.

Risk Factors

High scientific risk associated with the efficacy and safety of TCR therapies in solid tumors.

Intense competition from numerous well-funded biotechs and pharma in the immuno-oncology space.

Heavy reliance on external capital as a pre-revenue, pre-clinical company with a long path to market.

Competitive Landscape

Captain T Cell competes in the rapidly evolving TCR therapy space against companies like Adaptimmune, Immunocore, T-Cure Bioscience, and numerous stealth-mode biotechs. Larger pharmaceutical companies, such as GlaxoSmithKline (partnered with Adaptimmune) and Bristol Myers Squibb, are also active through partnerships and acquisitions, raising the competitive bar for discovery, development, and commercialization.

More companies in Cell & Gene Therapy →More companies in Germany →